Physician profile
Lawrence R Clarke
NPI 1386686228
$2,471.65
in general payments reported to CMS, 2019-2025
15 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.56 · 2020: $78.57 · 2021: $202 · 2022: $499 · 2023: $378 · 2024: $607 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $760.12 | 2022-2025 | |
| Genzyme Corporation | $415.76 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $291.32 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $268.58 | 2020-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $151.06 | 2019-2024 | Dupixent |
| Optinose US, INC. | $130.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $121.82 | 2024 | Breztri |
| Medtronic, INC. | $117.35 | 2023-2025 | Propel, Sinuva |
| Hikma Pharmaceuticals USA | $67.37 | 2024-2025 | Ryaltris |
| Acclarent, INC | $50.24 | 2021-2022 | |
| Medtronic USA, INC. | $23.83 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.70 | 2021 | |
| Integra Lifesciences Corporation | $22.92 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Phadia US INC. | $14.05 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.